These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10578011)

  • 21. Revascularization techniques in acute myocardial infarction.
    Gorman RC; Gorman JH
    N Engl J Med; 2000 Dec; 343(24):1815. PubMed ID: 11185605
    [No Abstract]   [Full Text] [Related]  

  • 22. [Adjuvant therapy with a glycoprotein IIb-IIa inhibitor (abciximab) in coronary angioplasties with a high thrombotic risk].
    Matos V; Marques AM; Oliveira H; Ramos D; Lopes P; Camacho M; Gonsalves A
    Rev Port Cardiol; 1998 Dec; 17(12):1001-5. PubMed ID: 9973861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of angioplasty with stenting in acute myocardial infarction.
    Herrmann HC
    N Engl J Med; 2002 Aug; 347(5):367-8; author reply 367-8. PubMed ID: 12151478
    [No Abstract]   [Full Text] [Related]  

  • 24. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
    Mesquita A; Baptista J; Palos J; Seabra-Gomes R
    J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.
    Herrmann HC; Swierkosz TA; Kapoor S; Tardiff DC; DiBattiste PM; Hirshfeld JW; Klugherz BD; Kolansky DM; Magness K; Valettas N; Wilensky RL
    Am J Cardiol; 2002 Jun; 89(11):1293-7. PubMed ID: 12031731
    [No Abstract]   [Full Text] [Related]  

  • 26. GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'.
    Montalescot G
    Eur Heart J; 2002 Feb; 23(4):259-60. PubMed ID: 11812056
    [No Abstract]   [Full Text] [Related]  

  • 27. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
    Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis.
    Berkompas DC
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):272-4. PubMed ID: 9829886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
    Topol EJ
    Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    Osman F; Qaisar S; El Gaylani N; Pitt M
    JAMA; 2005 Oct; 294(13):1616-7; author reply 1617-8. PubMed ID: 16204658
    [No Abstract]   [Full Text] [Related]  

  • 32. Avoidance of adverse events in restenotic lesions with abciximab?
    Linnemeier TJ
    J Invasive Cardiol; 2000 Nov; 12(11):545-6. PubMed ID: 11060564
    [No Abstract]   [Full Text] [Related]  

  • 33. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
    Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "IIb or not IIb or maybe IIb?" Is that the question? Or is it "which IIb and to whom?".
    Brinker JA
    Catheter Cardiovasc Interv; 2000 Oct; 51(2):145-6. PubMed ID: 11025565
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
    Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
    J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    De Luca L; Sardella G
    JAMA; 2005 Oct; 294(13):1617; author reply 1617-8. PubMed ID: 16204659
    [No Abstract]   [Full Text] [Related]  

  • 37. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.